A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Trial Profile

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs ALLN 177 (Primary)
  • Indications Primary hyperoxaluria
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2018 Status changed from planning to not yet recruiting.
    • 20 Dec 2017 New trial record
    • 14 Dec 2017 According to an Allena Pharmaceuticals media release, the company plans to initiate this study in the first quarter of 2018, with interim data expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top